UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of
The
Securities Exchange Act of 1934
Date
of
Report (Date of earliest event reported) October 14, 2005
Advaxis,
Inc.
|
(Exact
name of registrant as specified in its
charter)
|
Colorado
|
00028489
|
84
- 1521955
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
212
Carnegie
Center #206, Princeton, NJ
|
08546
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant’s
telephone number, including area code (201)
750-2347
|
(Former
name or former address, if changed since last
report.)
|
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act
(17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act
(17 CFR 240.13e-4(c))
Item
8.01. Other
Events
On
February 21, 2006, the Registrant issued a press release announcing that
regulators have allowed the company to initiate Phase I/II clinical testing
with
its lead compound, Listeria-based cancer vaccine, Lovaxin C. Lovaxin C, which
specifically targets cervical cancer in women, will be tested for the first
time
in humans in this study.
The
Advaxis vaccine Lovaxin C is a therapeutic designed to treat women who have
developed cervical cancer as a result of an HPV infection.
Advaxis
expects to begin dosing at multiple center sites by the end of February. The
study will be conducted at Hadassah Hospital in Jerusalem, The Institute of
Oncology and Radiology in Belgrade, which treats several hundred cervical cancer
patients every year, and at two facilities in Mexico. The first regulatory
approval has been received for Belgrade, with approvals for Israel and Mexico
in
review and anticipated shortly. Advaxis expects to announce the data from these
trials in the second half of 2006.
See
Registrant’s press release attached hereto as Exhibit 99.1.
Item
9.01. Financial
Statements and Exhibits
a) Not
applicable.
b) Not
applicable.
c) Exhibits
99.1. |
Press Release, dated February 21, 2006
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
|
|
ADVAXIS,
INC. |
|
|
|
Dated: February
24, 2005 |
By: |
/s/ Roni
Appel |
|
Name: Roni
Appel |
|
Title:
President and Chief
Executive
Officer
|